Your browser doesn't support javascript.
loading
ASO Visual Abstract: Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia, Daryl K A; Sundar, Raghav; Kim, Guowei; Ang, Jia Jun; Lum, Jeffrey H Y; Nga, Min En; Goh, Giap Hean; Seet, Je Ee; Chee, Cheng Ean; Tan, Hon Lyn; Ho, Jingshan; Ngoi, Natalie Y L; Lee, Matilda X W; Muthu, Vaishnavi; Chan, Gloria H J; Pang, Angela S L; Ang, Yvonne L E; Choo, Joan R E; Lim, Joline S J; Teh, Jun Liang; Lwin, Aung; Soon, Yuen; Shabbir, Asim; So, Jimmy B Y; Yong, Wei Peng.
Affiliation
  • Chia DKA; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
  • Sundar R; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Kim G; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Ang JJ; The N.1 Institute for Health, National University of Singapore, Singapore, Singapore.
  • Lum JHY; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
  • Nga ME; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
  • Goh GH; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore.
  • Seet JE; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore.
  • Chee CE; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore.
  • Tan HL; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore.
  • Ho J; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Ngoi NYL; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Lee MXW; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Muthu V; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Chan GHJ; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Pang ASL; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Ang YLE; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Choo JRE; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Lim JSJ; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Teh JL; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Lwin A; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
  • Soon Y; Department of General Surgery, Ng Teng Fong General Hospital, Singapore, Singapore.
  • Shabbir A; Department of General Surgery, Ng Teng Fong General Hospital, Singapore, Singapore.
  • So JBY; Department of General Surgery, Ng Teng Fong General Hospital, Singapore, Singapore.
  • Yong WP; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
Ann Surg Oncol ; 29(13): 8608-8609, 2022 Dec.
Article in En | MEDLINE | ID: mdl-36207480

Full text: 1 Database: MEDLINE Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Language: En Year: 2022 Type: Article